Rein Therapeutics Enters Material Agreement, Faces Financial Obligations
Ticker: RNTX · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $6.0 million, $1.0 million, $0.95 million, $1, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-securities
TL;DR
Rein Therapeutics just signed a big deal, creating new financial obligations. Watch this space.
AI Summary
Rein Therapeutics, Inc. entered into a Material Definitive Agreement on September 8, 2025. This agreement creates a direct financial obligation for the company. The filing also notes unregistered sales of equity securities and includes financial statements and exhibits.
Why It Matters
This filing indicates Rein Therapeutics has entered into a significant agreement that will likely impact its financial standing and operational future.
Risk Assessment
Risk Level: medium — Entering into new material agreements and creating financial obligations can introduce financial risks and uncertainties for a company.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- September 8, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Rein Therapeutics?
The filing states that Rein Therapeutics, Inc. entered into a Material Definitive Agreement on September 8, 2025, but the specific details of the agreement are not provided in this excerpt.
What type of financial obligation does the agreement create for Rein Therapeutics?
The agreement creates a direct financial obligation for Rein Therapeutics, Inc., as indicated by the filing's inclusion of 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant'.
Has Rein Therapeutics engaged in any unregistered sales of equity securities?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information, indicating such sales have occurred.
What is the former name of Rein Therapeutics, Inc.?
Rein Therapeutics, Inc. was formerly known as Aileron Therapeutics, Inc., with a name change occurring on March 29, 2024.
Where is Rein Therapeutics, Inc. headquartered?
Rein Therapeutics, Inc. is located at 12407 N. Mopac Expy., Suite 250 #390, Austin, TX 78758.
Filing Stats: 874 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2025-09-09 08:00:22
Key Financial Figures
- $6.0 million — may request pre-paid advances of up to $6.0 million from Yorkville (each, a "Pre-Paid Advan
- $1.0 million — dvances. An initial Pre-Paid Advance of $1.0 million was purchased on the Effective Date by
- $0.95 million — Date by Yorkville, for net proceeds of $0.95 million. As of the date of this report, we have
- $1 — verage price per share of approximately $1.06, to Yorkville, which were offset aga
- $500,000 — to Yorkville, which were offset against $500,000 of the outstanding initial Pre-Paid Adv
- $1.0 m — purchased a second Pre-Paid Advance of $1.0 million, for which we received net procee
Filing Documents
- d47459d8k.htm (8-K) — 29KB
- 0001193125-25-198816.txt ( ) — 145KB
- rntx-20250908.xsd (EX-101.SCH) — 3KB
- rntx-20250908_lab.xml (EX-101.LAB) — 18KB
- rntx-20250908_pre.xml (EX-101.PRE) — 11KB
- d47459d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are filed with this report: Exhibit 10.1 Pre-Paid Advance Agreement, dated as of July 29, 2025, between the Registrant and YA II PN, Ltd. (Incorporated by reference from Registrant's Current Report on Form 8-K filed on July 30, 2025) Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: September 9, 2025 /s/ Timothy M. Cunningham Timothy M. Cunningham, Chief Financial Officer